390 related articles for article (PubMed ID: 27008542)
1. Efficacy and safety of D. pteronyssinus immunotherapy in local allergic rhinitis: a double-blind placebo-controlled clinical trial.
Rondón C; Campo P; Salas M; Aranda A; Molina A; González M; Galindo L; Mayorga C; Torres MJ; Blanca M
Allergy; 2016 Jul; 71(7):1057-61. PubMed ID: 27008542
[TBL] [Abstract][Full Text] [Related]
2. Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy.
Liu Y; Xing Z; Wang J; Geng C
Am J Rhinol Allergy; 2018 Nov; 32(6):458-464. PubMed ID: 30124065
[TBL] [Abstract][Full Text] [Related]
3. Clinical Response to Subcutaneous Dermatophagoides pteronyssinus Immunotherapy in Children with Allergic Rhinitis and Asthma Is Independent of Sensitization to Blomia tropicalis Allergens.
Chen S; Zheng Y; Chen B; Zhong H; Liao F; Wang L; Hui SF; Lai X
Int Arch Allergy Immunol; 2019; 178(2):201-210. PubMed ID: 30544116
[TBL] [Abstract][Full Text] [Related]
4. Immunologic alterations and efficacy of subcutaneous immunotherapy with Dermatophagoides pteronyssinus in monosensitized and polysensitized patients.
Soyyigit S; Guloglu D; Ikinciogullari A; Secil D; Oztuna D; Mungan D; Misirligil Z; Sin BA
Ann Allergy Asthma Immunol; 2016 Mar; 116(3):244-251.e2. PubMed ID: 26945497
[TBL] [Abstract][Full Text] [Related]
5. Specific immunotherapy in local allergic rhinitis: A randomized, double-blind placebo-controlled trial with Phleum pratense subcutaneous allergen immunotherapy.
Rondón C; Blanca-López N; Campo P; Mayorga C; Jurado-Escobar R; Torres MJ; Canto G; Blanca M
Allergy; 2018 Apr; 73(4):905-915. PubMed ID: 29168570
[TBL] [Abstract][Full Text] [Related]
6. The Functional IgE-Blocking Factor Induced by Allergen-Specific Immunotherapy Correlates with IgG4 Antibodies and a Decrease of Symptoms in House Dust Mite-Allergic Children.
Zhao D; Lai X; Tian M; Jiang Y; Zheng Y; Gjesing B; Zhong N; Spangfort MD
Int Arch Allergy Immunol; 2016; 169(2):113-20. PubMed ID: 27049773
[TBL] [Abstract][Full Text] [Related]
7. Onset and dose-related efficacy of house dust mite sublingual immunotherapy tablets in an environmental exposure chamber.
Nolte H; Maloney J; Nelson HS; Bernstein DI; Lu S; Li Z; Kaur A; Zieglmayer P; Zieglmayer R; Lemell P; Horak F
J Allergy Clin Immunol; 2015 Jun; 135(6):1494-501.e6. PubMed ID: 25636947
[TBL] [Abstract][Full Text] [Related]
8. The efficacy and safety of two commercial house dust mite extracts for allergic rhinitis: a head-to-head study.
Li J; Wu Y; Yang Y; Huang N; Li W; Zhang S; Jiang Q; Yang L; Zhu R
Int Forum Allergy Rhinol; 2019 Aug; 9(8):876-882. PubMed ID: 31322838
[TBL] [Abstract][Full Text] [Related]
9. Randomized dose-response study of subcutaneous immunotherapy with a Dermatophagoides pteronyssinus extract in patients with respiratory allergy.
Moreno V; Alvariño M; Rodríguez F; Roger A; Peña-Arellano MI; Lleonart R; Pagán JA; Navarro JA; Navarro LA; Vidal C; Ponte-Tellechea A; Gómez-Fernández MC; Madariaga-Goirigolzarri B; Asturias JA; Hernández-Fernandez de Rojas D
Immunotherapy; 2016; 8(3):265-77. PubMed ID: 26757045
[TBL] [Abstract][Full Text] [Related]
10. Fast onset of action of sublingual immunotherapy in house dust mite-induced allergic rhinitis: a multicenter, randomized, double-blind, placebo-controlled trial.
Wang DH; Chen L; Cheng L; Li KN; Yuan H; Lu JH; Li H
Laryngoscope; 2013 Jun; 123(6):1334-40. PubMed ID: 23616386
[TBL] [Abstract][Full Text] [Related]
11. SQ house dust mite sublingually administered immunotherapy tablet (ALK) improves allergic rhinitis in patients with house dust mite allergic asthma and rhinitis symptoms.
Mosbech H; Canonica GW; Backer V; de Blay F; Klimek L; Broge L; Ljørring C
Ann Allergy Asthma Immunol; 2015 Feb; 114(2):134-40. PubMed ID: 25624131
[TBL] [Abstract][Full Text] [Related]
12. Early Intervention Improves Clinical Responses to House Dust Mite Immunotherapy in Allergic Rhinitis Patients.
Qi S; Chen H; Huang N; Li W; Liu G; Wang Y; Hu L; Wang X; Zhang W; Zhu R
Int Arch Allergy Immunol; 2016; 171(3-4):234-240. PubMed ID: 28049194
[TBL] [Abstract][Full Text] [Related]
13. Safety of house dust mite sublingual immunotherapy standardized quality tablet in children allergic to house dust mites.
Maloney J; Prenner BM; Bernstein DI; Lu S; Gawchik S; Berman G; Kaur A; Li Z; Nolte H
Ann Allergy Asthma Immunol; 2016 Jan; 116(1):59-65. PubMed ID: 26553448
[TBL] [Abstract][Full Text] [Related]
14. Immediate and dual response to nasal challenge with Dermatophagoides pteronyssinus in local allergic rhinitis.
López S; Rondón C; Torres MJ; Campo P; Canto G; Fernandez R; Garcia R; Martínez-Cañavate A; Blanca M
Clin Exp Allergy; 2010 Jul; 40(7):1007-14. PubMed ID: 20337651
[TBL] [Abstract][Full Text] [Related]
15. [The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma].
Yepes-Núñez JJ; Gómez C; Espinoza Y; Cardona R
Biomedica; 2014; 34(2):282-90. PubMed ID: 24967933
[TBL] [Abstract][Full Text] [Related]
16. Effective treatment of house dust mite-induced allergic rhinitis with 2 doses of the SQ HDM SLIT-tablet: Results from a randomized, double-blind, placebo-controlled phase III trial.
Demoly P; Emminger W; Rehm D; Backer V; Tommerup L; Kleine-Tebbe J
J Allergy Clin Immunol; 2016 Feb; 137(2):444-451.e8. PubMed ID: 26292778
[TBL] [Abstract][Full Text] [Related]
17. Specific IgE and IgG4 Profiles of House Dust Mite Components in Allergen-Specific Immunotherapy.
Yang L; Yang Y; Xu Q; Zhang W; Jiang Q; Li W; Wang Y; Ma D; Lin X; Sun B; Zhu R
Front Immunol; 2021; 12():786738. PubMed ID: 35197963
[TBL] [Abstract][Full Text] [Related]
18. House dust mite sublingual immunotherapy: a double-blind, placebo-controlled study in elderly patients with allergic rhinitis.
Bozek A; Ignasiak B; Filipowska B; Jarzab J
Clin Exp Allergy; 2013 Feb; 43(2):242-8. PubMed ID: 23331565
[TBL] [Abstract][Full Text] [Related]
19. Sublingual immunotherapy in children with allergic rhinoconjunctivitis mono-sensitized to house-dust-mites: a double-blind-placebo-controlled randomised trial.
Aydogan M; Eifan AO; Keles S; Akkoc T; Nursoy MA; Bahceciler NN; Barlan IB
Respir Med; 2013 Sep; 107(9):1322-9. PubMed ID: 23886432
[TBL] [Abstract][Full Text] [Related]
20. Functional and Immunoreactive Levels of IgG4 Correlate with Clinical Responses during the Maintenance Phase of House Dust Mite Immunotherapy.
Feng M; Su Q; Lai X; Xian M; Shi X; Wurtzen PA; Qin R; Zeng X; Li J
J Immunol; 2018 Jun; 200(12):3897-3904. PubMed ID: 29728509
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
